NASDAQ · RKTO
Rocket One Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for RKTO: Nov 11, 2026
Rocket One Inc. Common Stock is estimated to report earnings on 11/11/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. The reported EPS for the same quarter last year was $-0.3.
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Fintel · MarketBeat- RTTNews · Sep 22, 9:21 AM EDTRocket One To Acquire Tracer Drone Technologies(RTTNews) – Tuesday, Rocket One, Inc. (RKTO), an AI-based semiconductor infrastructure company, announced that it has entered into a Membership Interest Purchase Agreement to acquire all of the issued and outstanding membership interests of Tracer Drone Technologies, LLC, a New J
- RTTNews · Apr 17, 10:38 AM EDTWeekly Buzz: FDA Okays TVTX, PHG; Rejects REPL; AIP Snaps Up AVNS; PDS, HOTH, SYRE, Paces Trials(RTTNews) – This week's biotech landscape witnessed regulatory approvals across the U.S., Taiwan, and Europe, alongside FDA rejections, collaborations, acquisitions, and positive data readouts spanning multiple therapeutic areas, including Colorectal Cancer, Obesity and Fatty Liv
- RTTNews · Apr 14, 6:27 AM EDTHoth Therapeutics Soars On Positive HT-VA Study Data Of GDNF In Obesity And Fatty Liver Disease(RTTNews) – Hoth Therapeutics, Inc. (HOTH), a clinical-stage biopharmaceutical company, saw its shares surge by more than 55% in the pre-market after the firm announced positive data from its HT-VA study, which evaluated the effects of parenteral GDNF or Glial Cell-Derived Neurot
- RTTNews · Apr 2, 5:32 AM EDTHoth Therapeutics Unveils $2 Mln Direct Offering Of Shares; Eyes Up To $4.4 Mln With Warrants(RTTNews) – Hoth Therapeutics, Inc. (HOTH), a clinical-stage biopharmaceutical company, announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 2.85 million shares at an offering price of $0.70 per share in a registered direct offeri
- RTTNews · Feb 10, 8:55 AM ESTHoth Therapeutics Says GDNF Beats Semaglutide In Preclinical Obesity, Liver Disease Study New Data(RTTNews) – Hoth Therapeutics, Inc. (HOTH), a patient-focused biopharmaceutical company, Tuesday announced preclinical data from its VA-backed study on glial cell-derived neurotrophic factor (GDNF) as a novel treatment for obesity and metabolic-associated steatotic liver disease
- Fintel · Feb 4, 10:11 AM ESTHoth Therapeutics (HOTH) Price Target Increased by 11.11% to 5.10The average one-year price target for Hoth Therapeutics (NasdaqCM:HOTH) has been revised to $5.10 / share. This is an increase of 11.11% from the prior estimate of $4.59 dated January 11, 2026. The price target is an average of many targets provided by analyst
- RTTNews · Jan 21, 10:04 AM ESTHoth Secures Key China Patent For HT-KIT Cancer Program, Strengthening Global IP Position(RTTNews) – Hoth Therapeutics Inc. (HOTH), has received approval from the China National Intellectual Property Administration for a major patent covering its HT-KIT cancer program, expanding international protection for the company's targeted oncology platform.
- RTTNews · Jan 2, 9:20 AM ESTHoth Therapeutics Files Two Provisional Patents To Build Oncology Dermatology Platform(RTTNews) – Hoth Therapeutics (HOTH) has filed two U.S. provisional patent applications that expand its intellectual property portfolio and lay the foundation for a new oncology-focused dermatology platform aimed at treating skin toxicities caused by modern cancer therapies.
- Fintel · Dec 6, 10:58 AM ESTHoth Therapeutics (HOTH) Price Target Increased by 12.50% to 4.59The average one-year price target for Hoth Therapeutics (NasdaqCM:HOTH) has been revised to $4.59 / share. This is an increase of 12.50% from the prior estimate of $4.08 dated November 14, 2025. The price target is an average of many targets provided by analys
- Fintel · Dec 4, 7:05 PM ESTD. Boral Capital Maintains Hoth Therapeutics (HOTH) Buy RecommendationFintel reports that on December 4, 2025, D. Boral Capital maintained coverage of Hoth Therapeutics (NasdaqCM:HOTH) with a Buy recommendation. Analyst Price Forecast Suggests 240.00% Upside
- MarketBeat · Sep 9, 6:45 PM EDT3 Under-the-Radar Biotechs Under $5 That Could Soar 200%Investing in biotechnology stocks is typically reserved for speculative investors. For starters, many of these companies are clinical or pre-clinical stage companies. They’re not yet profitable, and many are even pre-revenue, meaning the long-term payoff will likely be years awa
- RTTNews · Sep 2, 9:34 AM EDTHoth Therapeutics: HT-KIT Surpasses Preclinical Milestones(RTTNews) – Hoth Therapeutics, Inc. (HOTH) announced combined positive findings from multiple preclinical programs evaluating its precision antisense candidate HT-KIT, including compelling anti-tumor efficacy, and new GLP-validated bioanalytical results that exceeded internationa
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Rocket One Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.